The use of polymeric devices for controlled sustained delivery of drugs is a promising approach for the prevention of HIV-1 infection. Unfortunately, certain microbicides, when topically applied vaginally, may be cytotoxic to vaginal epithelial cells and the protective microflora present within the female genital tract. In this study, we evaluated the impact of hydroxychloroquine (HCQ)-loaded, reservoir-type, polyurethane intravaginal rings (IVRs) on the growth of Lactobacillus crispatus and Lactobacillus jensenii and on the viability of vaginal and ectocervical epithelial cells. The IVRs were fabricated using hot-melt injection molding and were capable of providing controlled release of HCQ for 24 days, with mean daily release rates of 17.01 ؎ 3.6 g/ml in sodium acetate buffer (pH 4) and 29.45 ؎ 4.84 g/ml in MRS broth (pH 6.2). Drug-free IVRs and the released HCQ had no significant effects on bacterial growth or the viability of vaginal or ectocervical epithelial cells. Furthermore, there was no significant impact on the integrity of vaginal epithelial cell monolayers, in comparison with controls, as measured by transepithelial electrical resistance. Overall, this is the first study to evaluate the effects of HCQ-loaded IVRs on the growth of vaginal flora and the integrity of vaginal epithelial cell monolayers.
B
ased on a study conducted with 3,400 women in the United States by the National Health and Nutrition Examination Survey, 29% of women 14 to 49 years of age live with bacterial vaginosis (BV), the most common bacterial infection of the female genital tract (FGT) (1, 2) . It was estimated that, in 2014, more than 36.9 million people globally were infected with human immunodeficiency virus (HIV) (3) . More than 50% of the individuals infected with HIV are women, with heterosexual transmission being the main route of infection (4) . Although BV, HIV, and other sexually transmitted infections occur via the FGT, conventional treatment strategies involve oral administration of drugs. Most of those therapeutic strategies have failed, because orally administered drugs can be highly metabolized by the liver before being absorbed into the systemic circulation and reaching the FGT. Increasing the administered dose may not be possible, since this can result in severe systemic toxicity. The ideal treatment approach for infections or diseases affecting the FGT would be to deliver drugs locally via the vagina, to increase therapeutic effects while reducing systemic toxicity.
Numerous intravaginal products have been developed for the treatment of local infections, including semisolid ointments, creams, suppositories, and vaginal gels (5, 6) . Studies have shown that patient compliance with respect to semisolid dosage forms is low (7) . Major drawbacks include the fact that treatment requires daily applications and can be messy, and there can be leakage of the product, resulting in reduced therapeutic efficacy. To overcome some of these problems, specialized drug delivery systems, such as intravaginal rings (IVRs), have been developed (8) . IVRs can be designed to provide sustained controlled drug release, ultimately resulting in increased patient adherence (9) . To date, IVRs have been approved by the FDA for contraception and hormone replacement therapy (10) . Recently, researchers have begun investigating the potential application of IVRs as microbicides (products topically applied vaginally for the treatment or prevention of sexually transmitted infections) and for the treatment of BV (8, 11) . The major advantage of IVRs versus gels or tablets is the fact that IVRs can provide sustained release (Ͼ14 days) of drugs for long-term therapy, eliminating the need for daily drug administration (8, 13) . Once IVRs are inserted by the patients, they can remain within the FGT for long periods of time and will not interfere with sexual intercourse (14) . Upon completion of the therapy cycle, the patients can easily remove the IVRs themselves. In order to develop effective IVRs for therapeutic applications, it is important to take into consideration the nature of the drug and the polymer used for IVR fabrication (15) . For example, IVRs must not have any significant side effects on the normal flora of the FGT. Many microorganisms live in the FGT and protect the mucosal environment against pathogenic bacteria. Studies have shown that changes in the levels of the Lactobacillaceae family (most abundant flora in the vagina) lead to the growth of pathogenic bacteria, resulting in inflammation of the FGT (16). We previously described the fabrication of novel reservoir-type IVRs for controlled sustained delivery of the immunomodulatory drug hydroxychloroquine (HCQ), as a potential strategy for prevention of HIV-1 (8) . The IVRs demonstrated no significant effects on the proliferation of vaginal epithelial cells or on the production of proinflammatory cytokines in vitro. However, the effects of the developed system on the vaginal microflora and the integrity of the vaginal epithelial cell monolayer were not addressed. Since these are critical parameters for the development of a biocompatible microbicide, the current study investigated the effects of drug-free IVRs and HCQ-loaded IVRs on vaginal lactobacilli, the main components of the normal vaginal flora, as well as the integrity of the vaginal epithelial cell monolayer. This is the first study to evaluate the effects of HCQ-loaded IVRs on the growth of vaginal flora.
MATERIALS AND METHODS

Materials.
Lactobacillus jensenii (ATCC 55920) and Lactobacillus crispatus (ATCC 33820) were purchased from the American Type Culture Collection (ATCC) (Rockville, MD, USA). Lactobacillus MRS broth and agar were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Medical-grade, nonbiodegradable, polyether urethane (PU) Tecophilic HP-60D-35 was purchased from Lubrizol (Wickliffe, OH, USA). HCQ was purchased from TCI America (Portland, OR, USA). High-performance liquid chromatography (HPLC)-grade water, methanol, and acetonitrile were obtained from VWR International (Batavia, IL, USA). Methocel K100M premium hydroxypropyl methylcellulose (HPMC) was kindly supplied by the Dow Chemical Co. (New Milford, CT, USA). The human vaginal epithelial cell line VK2/E6E7 (ATCC CRL-2616), the human ectocervical epithelial cell line Ect1/E6E7 (ATCC CRL2-614), and the human CD4 ϩ T-cell line Sup-T1 (CRL-1942) were obtained from the ATCC. Keratinocyte-serum-free medium (K-SFM), recombinant human epidermal growth factor, and bovine pituitary extract were obtained from Life Technologies (Carlsbad, CA, USA). Trypsin-EDTA, penicillin-streptomycin solution, and fetal bovine serum (FBS) were purchased from Gibco Life Technologies (Burlington, ON, Canada).
Fabrication of IVRs. PU HP-60D-35 pellets were dried overnight at 80°C, in an oven, prior to the fabrication of IVRs. The pellets were melted using a hot-melt injection molder (Medium Machinery, LLC, Woodbridge, VA, USA) at 160°C and then were directed into a preheated mold for the fabrication of macaque-size reservoir-type IVRs (Fig. 1A) . The outer diameter for the macaque-size IVRs is 25 mm, and the cross-sectional diameter is 5 mm. The wall thickness of the IVRs is 0.75 mm. A digital caliper was used for all measurements.
Semisolid HCQ-HPMC preparation and HCQ extraction. The lumen of the IVRs was filled with semisolid HCQ-HPMC (at a 1:1 [wt/wt] ratio). Briefly, HCQ-HPMC was prepared by weighing 160 mg of HCQ and dissolving it in 1.28 ml of distilled water; 160 mg of HPMC was then added to the dissolved HCQ, and the components were gently mixed with a spatula. The mixture was then transferred into a 5-ml syringe connected to a second syringe via tubing. The contents of the syringe were passed back and forth for 80 passes, to allow homogeneous mixing. Drug extraction was performed with random aliquots of the semisolid mixture and drug levels were analyzed using HPLC, to confirm homogeneity (see below for the HPLC method). Briefly, the HCQ-HPMC mixture (10 Ϯ 0.5 mg) was diluted with 1 ml of distilled water in a microcentrifuge tube and vortex-mixed at 2,000 rpm overnight at 4°C. The HCQ concentration was then analyzed by HPLC.
HPLC method. Quantification of HCQ was performed using a reverse-phase HPLC method described previously (8) . Briefly, a Shimadzu LC-2010A HPLC instrument was used with a Waters Nova-Pak C 18 column (4 m, 3.9 mm by 150 mm) under isocratic conditions. The mobile phase included methanol, acetonitrile, and 58 mM sodium phosphate dibasic containing 15 mM heptanesulfonic acid (4:22:74 [vol/vol]); the pH was adjusted to 3.1 using concentrated phosphoric acid. The flow of the mobile phase was maintained at 1 ml/min and the column was maintained at 25°C for a run of 15 min, with injection of 40 l of sample. The peak for HCQ appeared at ϳ13 min. Release studies were performed in 5 ml of 25 mM sodium acetate buffer (pH 4) or MRS broth (pH 6.2), with shaking at 100 rpm on an orbital shaker at 37°C. Data represent the mean Ϯ SD (n ϭ 4).
In vitro release studies. HCQ-loaded IVR segments were sealed at both ends with silicone caps, to prevent leakage and to mimic drug release from a complete IVR, which would not have exposed ends. The segments were then sterilized using 70% isopropanol and dried overnight in a biosafety cabinet. Since the pH environment of a healthy FGT is ϳ4 (17), segments were placed in 5 ml of 25 mM sodium acetate buffer (pH 4) or 5 ml of MRS broth (pH 6.2) for a period of 24 days, in an incubating shaker (at 37°C and 100 rpm). Every 24 Ϯ 0.5 h, a sample of the release buffer was collected and the buffer was replenished, to maintain sink conditions. HPLC was used to evaluate the concentration of HCQ in each sample.
Evaluation of cytotoxic effects of HCQ and IVR segments on lactobacilli, vaginal and ectocervical epithelial cells, and immune cells. The microtiter broth dilution method was used to determine the MICs of HCQ for Lactobacillus crispatus and Lactobacillus jensenii, as described previously but with slight modifications (18) . Briefly, bacteria were grown on MRS agar, and one colony from the agar plate was transferred into 10 ml of MRS broth. The broth was incubated for 24 h at 37°C in 5% CO 2 . The culture medium was diluted to achieve a concentration of approximately 10 5 CFU/ml. One hundred microliters of MRS broth containing HCQ concentrations from 7 mg/ml to 0.05 mg/ml was added to each well of a 96-well plate. Gentamicin (10 g/ml) and blank MRS broth were used as controls. Five microliters of bacteria at 10 5 CFU/ml was dispensed into all wells of the plate except for one column that contained blank MRS broth (sterility control and blank for the microplate reader). All plates were incubated for 24 h at 37°C in 5% CO 2 . The turbidity of the samples was analyzed at 580 nm using a microplate reader (Biotek, Winooski, VT, USA).
VK2/E6E7, Ect1/E6E7, and Sup-T1 cells were seeded separately in 96-well plates, at a density of 2.5 ϫ 10 5 cells per well. After 2 h, 100 l of HCQ or 200 g/ml of nonoxynol-9 (N-9) (positive control) was added to each well for 24 h. MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent (40 l) was added, and the optical density of each well was analyzed at 490 nm after 1 h. Data were normalized and expressed as a percentage of the mean value of the negative control (untreated cells).
An elution assay was used to evaluate the cytotoxicity of drug-free IVR segments for bacteria. Briefly, IVR segments (100 Ϯ 0.5 mm) were sterilized in 70% isopropanol for 10 s and dried in a sterile biosafety cabinet. The segments were transferred aseptically into 10 ml of sterile phosphatebuffered saline (PBS) and incubated at 37°C for 1, 7, 15, and 30 days, at 100 rpm in an orbital shaker. The supernatants were collected aseptically, filtered through 0.2-m syringe filters, and stored at Ϫ80°C in 15-ml tubes until further analysis. Five-microliter aliquots of the diluted Lactobacillus crispatus and Lactobacillus jensenii (10 5 CFU/ml) were seeded in 96-well plates containing 100 l of medium (elution medium/growth medium ratio of 1:3) (19); 100-l aliquots of the positive control (gentamicin at 10 g/ml) and blank MRS broth were added as well. All plates were incubated for 24 h at 37°C in 5% CO 2 , and the turbidity of the samples was analyzed at 580 nm using a microplate reader.
IVR segments loaded with HCQ-HPMC were immersed in isopropanol for 10 min, to prevent any contamination from external bacteria, and were dried overnight in a biosafety cabinet. The segments were then placed in 5 ml of MRS broth for different times (1, 3, and 7 days) at 37°C and shaken at 100 rpm in an orbital shaker. One hundred microliters of broth containing elution medium from HCQ-loaded IVR segments was distributed in a 96-well plate for different time points, and 5 l of Lactobacillus jensenii or Lactobacillus crispatus (10 5 CFU/ml) was added to each well. Sterile MRS broth and MRS broth containing gentamicin (10 g/ml) were used as controls. The 96-well plates were incubated for 24 h at 37°C in 5% CO 2 , and turbidity was analyzed at 580 nm using a microplate reader.
IVR segments (150 Ϯ 5 mg) were incubated in 10 ml of K-SFM for 30 days; 1 M acrylamide in K-SFM was used as a positive control for induction of cell death, while plain K-SFM was used as a negative control (8) . One hundred microliters of elution medium was used to treat Ect1/E6E7 or VK2/E6E7 cells (2.5 ϫ 10 5 cells per well) for 24 h, followed by the addition of MTS reagent for 2 h. The optical density of each well was read at 490 nm, and data were normalized to the negative-control value.
In vitro evaluation of IVR segments on vaginal epithelial cell monolayer integrity. VK2/E6E7 cells were grown in K-SFM supplemented with 0.1 ng/ml recombinant human epidermal growth factor, 0.05 mg/ml bovine pituitary extract, 44.1 mg/liter calcium chloride, and 1% penicillinstreptomycin, at 37°C in 5% CO 2 . The cells were transferred onto a cell culture polycarbonate membrane insert (pore size, 1 m) at a density of 2 ϫ 10 5 cells per insert. The cells were seeded in 0.3 ml of culture medium, and the inserts were placed in 24-well plates containing 1 ml of medium. The cells were grown on the inserts for 3 days, and the integrity of the cell monolayers was evaluated by measuring changes in transepithelial electrical resistance (TEER) using a voltohmmeter (Millicell ERS-2; Millipore). After reaching a TEER value of ϳ30 ⍀ cm 2 (indicating an intact confluent monolayer of cultured cells on each insert) (20) , cells were exposed to HCQ-free IVR segments, HCQ-loaded IVR segments, or 50 g/ml free HCQ for 2 days. Untreated cells and cells treated with N-9 were used as controls.
Statistical analysis. Data are presented as the mean Ϯ standard deviation (SD). The n values refer to the numbers of replicates performed for each study. One-way analysis of variance was performed with all results, with P values of Ͻ0.05 considered to be significant.
RESULTS
In vitro release studies. HCQ-HPMC (1:1 [wt/wt])-loaded IVR segments demonstrated sustained release of HCQ over 24 days.
The mean daily release rate of HCQ was approximately 17.01 Ϯ 3.6 g/ml, with cumulative release of 2,041.80 Ϯ 180.21 g at day 24 (near-zero-order release profile, with a R 2 value of 0.999) (Fig.  1B) . Since the IVR segments were to be evaluated in the presence of lactobacilli grown in MRS broth, release studies were also conducted in MRS broth at pH 6.2 (Fig. 1B) . The release rate in MRS broth was significantly higher than that in sodium acetate buffer, with a mean daily release rate of 29.45 Ϯ 4.84 g/ml and cumulative release of 3,534.52 Ϯ 30.32 g at day 24 (near-zero-order release profile, with a R 2 value of 0.996). Evaluation of cytotoxic effects of HCQ and IVR segments on lactobacilli, vaginal and ectocervical epithelial cells, and immune cells. The lactobacilli most commonly found in the FGT, Lactobacillus crispatus and Lactobacillus jensenii, were chosen for determination of HCQ MICs. As shown in Fig. 2A , 0.05 mg/ml HCQ (approximately twice the amount released daily from a HCQ segment) had no significant impact on the growth of Lactobacillus jensenii or Lactobacillus crispatus. At a concentration of 7 mg/ml HCQ (more than 100 times the daily released concentration), significant inhibition of the growth of both types of bacteria was observed. Gentamicin (10 g/ml), the positive control, inhibited 100% of bacterial growth.
The potential cytotoxicity of HCQ for vaginal and ectocervical epithelial cells and T cells was investigated. Different concentrations of free HCQ were evaluated with the vaginal and ectocervical epithelial cell lines VK2/E6E7 and Ect1/E6E7, respectively, and with CD4
ϩ Sup-T1 cells (Fig. 2B) . HCQ concentrations of up to 4.34 g/ml did not elicit any significant cytotoxic effects. Concentrations of 43.4 g/ml significantly reduced Sup-T1 cell viability, and concentrations of Ն433.96 g/ml significantly reduced the viability of all three cell lines.
To determine the biocompatibility of the fabricated IVR segments, an elution assay was used to evaluate the cytotoxicity of drug-free and HCQ-containing IVR segments for lactobacilli and vaginal and ectocervical cells. Drug-free IVR segments had no significant effects on the growth of Lactobacillus jensenii or Lactobacillus crispatus after incubation for 30 days (Fig. 3) or on the viability of VK2/E6E7 and Ect1/E6E7 cells after 30 days, compared to controls. HCQ released from the IVR segments significantly reduced the growth of Lactobacillus crispatus after day 3 and day 7, but no significant changes in the growth of Lactobacillus jensenii were observed (Fig. 4) .
Assessment of transepithelial electrical resistance of VK2/ E6E7 cells. To evaluate the impact of our HCQ IVR system on vaginal epithelial cell monolayer integrity, the transepithelial electrical resistance (TEER) of the monolayer was determined. This assay measures the change in the electrical resistance of the cultured cells, which reflects observed changes in cell monolayer integrity. The mean TEER value for an intact monolayer of VK2/ E6E7 cells was approximately 30.55 Ϯ 1.7 ⍀ cm 2 , which is comparable to previously reported values (20) . Figure 5 presents the TEER values after treatment with free HCQ (50 g/ml), drugfree IVRs, or HCQ-loaded IVRs containing 1 mg/ml HCQ. No significant differences in TEER values were observed with any of the treatment groups, in comparison to the negative control, after 48 h. The positive control (N-9) decreased the TEER by 37.59 Ϯ 5.97% after 48 h.
DISCUSSION
The FGT is becoming an important site for both local and systemic drug delivery, particularly for the prevention of sexually transmitted infections, e.g., intravaginal microbicides. The benefits of intravaginal delivery include higher local drug concentrations and reduced systemic toxicity. As a result, there is an urgent need to develop effective safe microbicides that can prevent HIV-1 infection. Damage to the vaginal epithelial surface due to certain chemicals and drug carriers can cause inflammation of the FGT (21, 22) , resulting in increased risk of HIV acquisition, as observed in several failed microbicide trials (23, 24) . Furthermore, the majority of microbicide studies have focused on the ability of the microbicide to induce inflammation in vaginal epithelial and immune cells (25) . There is currently a lack of studies evaluating the effects of microbicides on the natural flora present in the FGT. Among the normal vaginal flora protecting the FGT, lactobacilli represent the main type of bacteria that establish the balance between pathogenic bacteria and healthy flora. Decreases in lactobacilli encourage overgrowth of pathogenic bacteria and can lead to inflammation and susceptibility to various sexually transmitted diseases (26) (27) (28) . Therefore, it is very important to assess the toxic effects of microbicides on lactobacilli, as well as their effects on vaginal epithelial cell monolayer integrity, to ensure that the microbicides do not disrupt the complex microenvironment.
HCQ is approved for the treatment of malaria, systemic lupus erythematous, and rheumatoid arthritis. A number of studies have also demonstrated its direct antiviral activity against HIV (29, 30) . Furthermore, HCQ is capable of maintaining the quiescent state of T cells, thereby reducing the number of target cells for HIV infection (31) . In our studies, we were able to obtain sustained zero-order release of HCQ from IVR segments for up to 24 days. The greater release observed in MRS broth versus sodium acetate buffer may be due to the high protein-binding capacity of HCQ itself (32) . The protein and lipid components present in MRS broth could act as a sink for HCQ during the release studies (32) . A study showed that HCQ at 4.34 g/ml was capable of suppressing early T-cell activation (29) . In the same study, higher concentrations of up to 43.4 g/ml were used to induce the immune quiescence of T cells and were found to be safe (29) . Based on our studies, our IVR system can provide daily release of HCQ at the necessary therapeutic concentration (4.34 g/ml) (33) to induce immune quiescence. To evaluate the safety of HCQ for lactobacilli, we treated the most common types of lactobacilli found in the FGT with different concentrations of HCQ. Lactobacillus crispatus and Lactobacillus jensenii are the main species of vaginal flora that produce hydrogen peroxide, according to a study conducted by Antonio and colleagues (34) . Lactobacilli also use the Bacterial growth was measured at 580 nm using a microplate reader. The viability of VK2/E6E7 and Ect1/E6E7 cells was determined after treatment with elution medium from drug-free IVR segments. The negative control (NC) for bacterial studies consisted of lactobacilli treated with drug-free culture medium, and the positive control (PC) consisted of lactobacilli treated with gentamicin (10 g/ml). The negative control for VK2/E6E7 and Ect1/E6E7 studies consisted of cells treated with drug-free culture medium, and the positive control consisted of cells treated with 1 M acrylamide. Data were normalized to the negative control and represent the mean Ϯ SD values (n ϭ 3) for bacterial studies and the mean Ϯ SD values (n ϭ 6) for VK2/E6E7 and Ect1/E6E7 studies. *, P Ͻ 0.05 versus the negative control.
FIG 4
Effects of drug-loaded IVR segments on cell growth and viability. Lactobacillus crispatus and Lactobacillus jensenii were treated for 24 h with medium containing HCQ released from drug-loaded IVR segments at various time points. Bacterial growth was measured at 580 nm using a microplate reader. The negative control (NC) consisted of lactobacilli treated with drug-free medium, and the positive control (PC) consisted of lactobacilli treated with medium containing gentamicin (10 g/ml). Data represent the mean Ϯ SD (n ϭ 4). *, P Ͻ 0.05 versus the negative control.
glycogen present in the vaginal tract to produce lactic acid, to maintain an acidic vaginal environment (pH 4.2 to 5) (17, 35) . The highest daily concentration of HCQ released in MRS broth from our reservoir IVR segment was nearly 35-fold lower than the highest concentration tested in the current study (1 mg/ml), which had no significant impact on bacterial growth ( Fig. 2A) . Concentrations higher than 1 mg/ml significantly inhibited the growth of both strains, which could be attributable to the bacteriostatic effects of HCQ (36) . Therefore, the level of HCQ released from our device is significantly lower than the levels that inhibit the growth of lactobacilli but is high enough to elicit a therapeutic effect within the FGT.
We also evaluated the effects of drug-free IVRs on bacterial growth. This was important, to ensure that there would be no degradation or unreacted polymer products leaching out of the IVRs with time. Based on our results, drug-free IVRs had no significant impact on the growth of lactobacilli (Fig. 3) . Furthermore, it is currently not known whether HCQ and IVRs have any synergistic effects. In our studies, HCQ-loaded IVR segments that were immersed in MRS broth for up to 7 days had no significant impact on Lactobacillus jensenii but there was a slight decrease in the growth of Lactobacillus crispatus with 3-day-and 7-day-immersed samples. One possible reason for this observation may involve the higher levels of HCQ accumulated within the 3-day and 7-day MRS broth samples. In the current study, IVR segments were incubated in broth medium for up to 7 days without changes in the broth medium. As a result, HCQ released from the IVR segments accumulated in the MRS broth during the entire 7-day study period (except when samples were collected on days 1, 3, and 7). Since normal FGTs produce vaginal secretions at 2 to 10 ml/day (37), HCQ released from the IVRs can be "washed out" of the FGT, resulting in lower vaginal HCQ concentrations.
Furthermore, it was important to determine whether our IVR system would be cytotoxic to the surrounding epithelial tissues and the underlying mucosal immune cells of the FGT. Therefore, we evaluated the impact of our IVR system on the viability of vaginal and ectocervical epithelial cell lines and a CD4 ϩ T-cell line. HCQ concentrations of up to 4.34 g/ml showed no significant effects (P Ͻ 0.05) on the viability of VK2/E6E7 vaginal epithelial cells, Ect1/E6E7 ectocervical epithelial cells, or Sup-T1 immune cells, compared to the negative control. Drug-free IVR segments also demonstrated no significant impact on the viability of these three cell lines over a period of 30 days.
Although we showed that our HCQ-loaded IVR segments had no significant effects on the viability of vaginal or ectocervical epithelial cells, CD4 ϩ T cells, and lactobacilli, it was not known whether there were any changes in the tight junctions of vaginal epithelial cells, which is a concern since this may increase the opportunities for viruses to penetrate the vaginal mucosal layer and to infect underlying immune cells (38) . As a result, we evaluated TEER values for VK2/E6E7 cell monolayers before and after exposure to HCQ alone, drug-free IVR segments, or HCQ-loaded IVR segments. All of the treatment groups demonstrated no significant effects on TEER values after 48 h, compared to the negative control, suggesting that the vaginal epithelial cell monolayers were still intact. This is the first study to evaluate the effects of HCQ-loaded IVRs on the growth of major strains of lactobacilli commonly found in the FGT. The amounts of HCQ released daily were within the therapeutic concentration range necessary to induce T-cell immune quiescence. The IVR system had no significant effects on the growth of Lactobacillus crispatus or Lactobacillus jensenii, the viability of vaginal or ectocervical epithelial cells or immune cells, or the integrity of vaginal epithelial cell monolayers. These promising results support further in vivo investigation of HCQ as a potential microbicide for the prevention of HIV-1 infection and other sexually transmitted infections.
